Akero Therapeutics, Inc.
Akero Therapeutics, Inc. (AKRO) Financial Performance & Income Statement Overview
Analyze Akero Therapeutics, Inc. (AKRO) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.
Akero Therapeutics, Inc. (AKRO) Income Statement & Financial Overview
Explore comprehensive income reports for Akero Therapeutics, Inc. AKRO, broken down by year and quarter.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $1000.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | -$1000.00 |
| Gross Profit Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| R&D Expenses | $69.57M | $69.29M | $72.23M | $55.32M |
| SG&A Expenses | $11.31M | $8.73M | $9.47M | $10.42M |
| Operating Expenses | $80.88M | $78.03M | $81.70M | $65.74M |
| Total Costs & Expenses | $0.00 | $78.03M | $81.70M | $65.74M |
| Interest Income | $0.00 | $9.20M | $10.24M | $10.98M |
| Interest Expense | -$1.15M | $1.20M | $1.25M | $1.23M |
| Depreciation & Amortization | $0.00 | $15000.00 | $1000.00 | $1000.00 |
| EBITDA | -$80.88M | -$68.81M | -$71.46M | -$54.76M |
| EBITDA Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | -$80.88M | -$78.03M | -$81.70M | -$65.74M |
| Operating Income Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| Other Income/Expenses (Net) | $10.16M | $8.001M | $9.00M | $9.75M |
| Income Before Tax | -$70.72M | -$70.02M | -$72.70M | -$55.99M |
| Income Before Tax Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$70.72M | -$70.02M | -$72.70M | -$55.99M |
| Net Income Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| EPS | -$0.90 | -$0.99 | -$1.05 | -$0.81 |
| Diluted EPS | -$0.90 | -$0.99 | -$1.05 | -$0.81 |
| Weighted Avg Shares Outstanding | $78.66M | $70.57M | $69.44M | $69.16M |
| Weighted Avg Shares Outstanding (Diluted) | $78.66M | $70.57M | $69.44M | $69.16M |
Financial performance has remained strong, with revenue growing from $0.00 in Q2 2024 to $0.00 in Q1 2025. Gross profit continued to perform well, with margins at N/A in the latest quarter. Operating income reached -$80.88M in Q1 2025, holding a steady N/A margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at -$80.88M. Net income dropped to -$70.72M, keeping EPS at -$0.90. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan